RNA
interference (RNAi) is a powerful tool capable of targeting virtually
any protein without
time-consuming and expensive drug development studies. However, due
to obstacles facing efficient and safe delivery, RNAi-based therapeutic
approach remains a challenge. Herein, we have designed and synthesized
a number of disulfide-constraining cyclic and hybrid peptides using
tryptophan and arginine residues. Our hypothesis was that peptide
structures would undergo reduction by intracellular glutathione (more
abundant in cancer cells) and unpack the small interfering RNA (siRNA)
from the peptide/siRNA complexes. A subset of newly developed peptides
(specifically, C4 and H4) exhibited effective
cellular internalization of siRNA (∼70% of the cell population;
monitored by flow cytometry and confocal microscopy), the capability
of protecting siRNA against early degradation by nucleases (monitored
by gel electrophoresis), minimal cytotoxicity in selected cell lines
(studied by cell viability and LC50 calculations), and
efficient protein silencing by 70–75% reduction in the expression
of targeting signal transducer and activator of transcription 3 (STAT3)
in human triple-negative breast cancer (TNBC) MDA-MB-231 cells, analyzed
using the Western blot technique. Our results indicate the birth of
a promising new family of siRNA delivery systems that are capable
of safe and efficient delivery, even in the presence of nucleases.